RETINAL PHARMACOTHERAPEUTICS

RETINAL PHARMACOTHERAPEUTICS

Editorial:
KARGER
Año de edición:
Materia
Oftalmología
ISBN:
978-3-318-05564-1
Páginas:
408
N. de edición:
1
Idioma:
Inglés
Ilustraciones:
83
Disponibilidad:
Disponible en 2 semanas

Descuento:

-5%

Antes:

307,84 €

Despues:

292,45 €

Preliminaries

Basic Sciences in the Retina
• Evolving Knowledge in Pharmacologic Treatments of Age-Related Macular Degeneration 3.
• Retinal Anatomy and Pathology
• Retinal Biochemistry, Physiology and Cell Biology
• Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors
• Ocular Immunity and Inflammation
• Complement Activation and Inhibition in Retinal Diseases
• Genetics in Retinal Diseases

Animal Models and Routes for Retinal Drug Delivery
• Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections
• Routes for Drug Delivery to the Retina: Topical, Transscleral, Suprachoroidal and Intravitreal Gas Phase Delivery
• Routes for Drug Delivery: Sustained-Release Devices
• Microspheres and Nanotechnology for Drug Delivery
• Thermo-Responsive Hydrogels for Ocular Drug Delivery

Retinal Diseases Amenable to Pharmacotherapy
• Nonneovascular Age-Related Macular Degeneration
• Neovascular Age-Related Macular Degeneration
• Diabetic Retinopathy and Diabetic Macular Edema
• Retinal Vein Occlusion
• Retinal Detachment and Proliferative Vitreoretinopathy
• Posterior Uveitis
• Choroidal Neovascularization Secondary to Myopia, Infection and Inflammation
• Ocular Infection: Endophthalmitis
• Treatment for Macular Telangiectasia Type 2
• Neovascular Glaucoma
• Retinal Hereditary and Degenerative/Dystrophic Diseases (Non-Age-Related Macular Degeneration)

Drugs and Mechanisms in Retinal Diseases
• Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases
• Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone
• Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab
• Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab
• Biologic Therapies: Anti-Tumor Necrosis Factor-a, Anti-Interleukins, Rituximab and Others
• Immunomodulatory Therapy in Uveitis
• Sirolimus for Retinal and Uveitic Diseases
• Fusion Proteins: Aflibercept (VEGF Trap-Eye)
• The Protein Kinase C Inhibitor: Ruboxistaurin
• Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy
• Platelet-Derived Growth Factor Inhibitors: A Potential Therapeutic Approach for Ocular Neovascularization
• Ocular Gene Therapy
• Neuroprotection and Retinal Diseases
• Photosensitizers and Photodynamic Therapy: Verteporfin
• Chemotherapy for Malignant Intraocular Tumors
• Antibiotics

Pharmacotherapy and Surgery
• Enzymatic Vitrectomy and Pharmacologic Vitreodynamics
• The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy

The Last Words
• Regulatory and Economic Considerations of Retinal Drugs
• Value-Based Medicine and Pharmacoeconomics
• Future Perspectives: Agents on the Horizon

Subject Index

The use of pharmacotherapeutics in the management of retinal diseases is rapidly evolving, and a favorable therapy for the patient. Today anti-VEGF agents are used for a range of indications from inflammation-related choroidal neovascularization to macular edema secondary to retinal vein occlusion or diabetic retinopathy. Beyond VEGF, there is an array of target areas under investigation – not only for vascular pathologies such as age-related macular degeneration and diabetic eye disease, but also for degenerative, infectious and inflammatory retinal conditions.
This publication discusses many aspects from basic research on the retina, to animal models for retinal drug delivery, retinal diseases that are amenable to pharmacotherapy and also drugs and mechanisms in retinal diseases. Anyone concerned with the management of retinal diseases - the general ophthalmologist and the retina specialist alike – will find this book indispensable reading.